tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BCAX Stock Latest News

Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs
The FlyBicara moved to Neutral from Early-Stage Biotech at Goldman Sachs
7h ago
BCAX
Bicara Therapeutics announces inducement grants
PremiumThe Fly
Bicara Therapeutics announces inducement grants
7d ago
BCAX
Bicara Therapeutics initiated with an Outperform at Citizens
PremiumThe Fly
Bicara Therapeutics initiated with an Outperform at Citizens
14d ago
BCAX
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
PremiumRatings
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
26d ago
BCAX
Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
PremiumRatings
Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
29d ago
BCAX
Bicara Sets Phase 3 Path for Ficerafusp Alfa
PremiumCompany AnnouncementsBicara Sets Phase 3 Path for Ficerafusp Alfa
1M ago
8K
BCAX
Bicara Therapeutics announces Phase 3 optimal dose of ficerafusp alfa
Premium
The Fly
Bicara Therapeutics announces Phase 3 optimal dose of ficerafusp alfa
1M ago
BCAX
Bicara Therapeutics initiated with a Buy at BTIG
Premium
The Fly
Bicara Therapeutics initiated with a Buy at BTIG
1M ago
BCAX
Bicara Therapeutics initiated with a Neutral at Mizuho
PremiumThe Fly
Bicara Therapeutics initiated with a Neutral at Mizuho
2M ago
BCAX
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda
PremiumRatings
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda
2M ago
BCAX
3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts
2M ago
BCAX
HASI
Bicara Therapeutics Reports Promising Phase 1b Data
PremiumCompany Announcements
Bicara Therapeutics Reports Promising Phase 1b Data
2M ago
8K
BCAX
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation
PremiumRatingsBuy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation
2M ago
BCAX
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating
Premium
Ratings
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating
2M ago
BCAX
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa
Premium
The Fly
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa
2M ago
BCAX
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating
PremiumRatings
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating
2M ago
BCAX
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract
PremiumRatings
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract
2M ago
BCAX
Bicara Therapeutics Inc. (BCAX) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Bicara Therapeutics Inc. (BCAX) Q3 Earnings Cheat Sheet
3M ago
BCAX
Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics
PremiumRatings
Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics
3M ago
BCAX
Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)
PremiumThe FlyBicara Therapeutics reports Q3 EPS (67c), consensus (53c)
3M ago
BCAX
Bicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
Premium
Company Announcements
Bicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
4M ago
BCAX
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
Premium
Company Announcements
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
4M ago
BCAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >